Company Information

    ScPharmaceuticals was founded on January 2014. The company is based in Lexington, MA, USA . The number of employees in scPharmaceuticals is less than 50. Scpharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.

    Here is how scPharmaceuticals describes itself: "Our proprietary subcutaneous furosemide for HF diuresis is delivered via an on-body infusor for the outpatient treatment of congestion in patients with HF."
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          scPharmaceuticals has received 3 rounds of venture funding. The total funding amount is around $126.6M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        scPharmaceuticals - Blog

                          • Site goes live

                          • Website goes live in November! Location: scpharmaceuticals.com Time: November 1, 2017 For more information, please contact us.The post Site goes live appeared first on scPharma.
                          • scPharmaceuticals Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide)

                          • FOR IMMEDIATE RELEASE: BURLINGTON, MA., — scPharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced that the 505(b)(2) New Drug Application (NDA) for Furoscix has been accepted for filing by the U.S. Food and Drug Administration (FDA).The post <span class="normalcase">scPharmaceuticals</span> Announces FDA Acceptance of NDA for Furoscix (subcutaneous furosemide) appeared first on scPharma.
                          • Poster on Performance Reliability of the scFurosemide Infusor for Subcutaneous Administration of a Novel Formulation of Furosemide in Patients with Heart Failure

                          • Rene L. Myers,1 PhD, James Udelson2, MD, Barbara Cornelius1, Christopher G. Lohan1, Javier Zugasti1, PhD, Pieter Muntendam1, MD 1scPharmaceuticals, Inc.; 2Tufts Medical Center Poster Performance Reliability of the scFurosemide Infusor for Subcutaneous Administration of a Novel Formulation of Furosemide in Patients with Heart Failure  The post Poster on Performance Reliability of the scFurosemide Infusor for Subcutaneous Administration of a Novel Formulation of Furosemide in Patients with Heart Failure appeared first on scPharma.
                          • John Tucker Appointed as Chief Executive Officer of scPharmaceuticals

                          • LEXINGTON, MA, April 26, 2017 /PRNewswire/ — scPharmaceuticals, Inc., a privately held pharmaceutical company transforming patient care and healthcare costs through innovative subcutaneous drug delivery, announced the appointment of John Tucker as president and chief executive officer, effective immediately. Mr. Tucker was also elected to the board of directors of scPharmaceuticals.The post John Tucker Appointed as Chief Executive Officer of <span class="normalcase">scPharmaceuticals</span> appeared first on scPharma.
                          • scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product

                          • LEXINGTON, Mass., January 24, 2017 /PRNewswire/ – scPharmaceuticals, Inc., a privately held pharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN). HFN is a clinical research initiative funded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The primary goal of the HFN is to conduct multiple clinical trials to evaluate treatments and strategies to improve management of acute and chronic heart failure.The post <span class="normalcase"><span class="normalcase">scPharmaceuticals</span></span> Announces Start of <span class="normalcase">SUBQ-HF</span> <span class="normalcase">NHLBI</span> Study with Its Subcutaneous Furosemide Product appeared first on scPharma.
                          • scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

                          • Funding supports preparation for commercial introduction of Furoscix™ and further advancement of the sc2Wear™ drug delivery platform.The post <span class="normalcase">scPharmaceuticals</span> Announces Closing of $45.6 Million in Series <span class="normalcase">B</span> Financing appeared first on scPharma.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *